7,839 Results

FDA approves Sutent to treat high risk patients post surgery with renal cell carcinoma.- Pfizer

 Added 14 hours ago

The FDA has approved Sutent (sunitinib malate) for the adjuvant treatment of adult patients who are at a high risk...

Trelegy Ellipta triple therapy meets EU approval for COPD

 Added 1 day ago

GlaxoSmithKline plc and Innoviva, Inc. announced that the European Commission has granted marketing authorisation for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, ‘FF/UMEC/VI’)...

World Pancreatic Cancer Day 2017

 Added 2 days ago

World Pancreatic Cancer Day 2017

The organisers of World Pancreatic Cancer Day 2017 are asking us to Demand better.

Trial analysis presented at the American Heart Association (AHA) shows Lixiana has greater reductions in ischaemic events compared to warfarin

 Added 2 days ago

Sub analysis of ENGAGE AF-TIMI 48 trial showed Lixiana has greater reductions in ischaemic events compared to warfarin.

New digital medicine system granted first approval

 Added 2 days ago

FDA approves Abilify Mycite to treat schizophrenia, depression and bipolar I disorder

 

Fasenra approved for treatment of severe asthma with eosinophilic phenotype

 Added 2 days ago

AstraZeneca and MedImmune, announced that the FDA has approved Fasenra (benralizumab) for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.

EMUC 2017

 Added 3 days ago

Tomorrow marks the start of EMUC 2017 in Barcelona, Spain.

New data shows 31% reduction in CardioVascular death with canakinumab

 Added 3 days ago

Novartis announced results from a new analysis of the Phase III CANTOS study presented by Dr. Paul Ridker at the American Heart Association (AHA) Scientific Sessions 2017

Innovative study presented at the American College of Rheumatology compare biosimilars with their reference medicines

 Added 3 days ago

Sandoz announces data from four clinical studies comparing proposed biosimilar adalimumab & biosimilar rituximab with their reference medicines, Humira and MabThera/Rituxan.

Landmark trial data demonstrates reduced risk of CV death in patients with Type 2 diabetes and peripheral artery disease

 Added 3 days ago

New data showed that Jardiance (empagliflozin) reduced the risk of cardiovascular death compared with placebo when added to standard of care in adults with type 2 diabetes and peripheral artery disease.

Load more